OmicsPred as a centralized resource for genetic prediction of multi-omic traits.
Explore the source record for details and available documents.
Journal Article↗
Biomedical subjects
Michael Inouye
Publications and source records attributed to Michael Inouye.
OmicsPred as a centralised resource for genetic prediction of multi-omic traits.
Genetic prediction of multi-omic data has emerged as a cost-effective alternative to direct omics profiling, particularly useful for identifying molecular features associated with disease susceptibility. However, despite its popularity, multi-omic imputation models are fragmented across studies, hindering findability, accessibility, interoperability and re-use. To address this, we developed OmicsPred (https://www.omicspred.org), a centralised platform for the deposition and dissemination of genetic prediction models of multi-omic traits. OmicsPred unifies the most commonly used molecular imputation models (e.g. from PredictDB) and other published studies totalling 3,339,469 prediction models spanning transcriptomic, proteomic, and metabolomic traits (as of May 2026). Each model is accompanied by metadata describing score development and predictive performance, and distributed in formats compatible with popular analytic tools, such as PGS Catalog Calculator and MetaXcan. To demonstrate the utility of the resource for systematic target discovery, we perform a multi-omic phenome-wide association analysis in Million Veterans Program data.
Journal Article↗
Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities.
Genomics can provide insight into the etiology of type 2 diabetes and its comorbidities, but assigning functionality to non-coding variants remains challenging. Polygenic scores, which aggregate variant effects, can uncover mechanisms when paired with molecular data. Here, we test polygenic scores for type 2 diabetes and cardiometabolic comorbidities for associations with 2,922 circulating proteins in the UK Biobank. The genome-wide type 2 diabetes polygenic score associates with 617 proteins, of which 75% also associate with another cardiometabolic score. Partitioned type 2 diabetes scores, which capture distinct disease biology, associate with 342 proteins (20% unique). In this work, we identify key pathways (e.g., complement cascade), potential therapeutic targets (e.g., FAM3D in type 2 diabetes), and biomarkers of diabetic comorbidities (e.g., EFEMP1 and IGFBP2) through causal inference, pathway enrichment, and Cox regression of clinical trial outcomes. Our results are available via an interactive portal ( https://public.cgr.astrazeneca.com/t2d-pgs/v1/ ).
Humans↗